Efficacy of Celecoxib for Early Postoperative Pain Management in Hip Arthroscopy: A Prospective Randomized Placebo-Controlled Study

The efficacy and safety of early initiation of preoperative analgesia with celecoxib in patients underwent arthroscopic knee surgery

“…But for the consideration of cost-saving and toxicity of medicine itself, we thought pre-emptive analgesia in PEA group (1 hour before operation) is the optimal choice for AKS. [ 12 , 19 , 23 ]…”

“…The benefits of pain relief by celecoxib for preoperative analgesia have been observed in patients with hip arthroscopy. [ 6 , 12 , 13 ] To date, a few studies also illustrate that preoperative administration of celecoxib in AKS decreases patients’ pain score and lowers adverse effects. [ 7 , 14 ] However, few studies about the most appropriate time of celecoxib initiation before surgery have been explored in patients with AKS.…”

Efficacy of preemptive analgesia versus postoperative analgesia of celecoxib on postoperative pain, patients’ global assessment and hip function recovery in femoroacetabular impingement patients underwent hip arthroscopy surgery

“…Regarding to this, perioperative pain management with efforts to control pain in the acute postoperative period is needed. Celecoxib, a type of non-steroidal antiinflammatory drug (NSAID), presents with the distinct characteristics including rapid absorption, preferential distribution into inflamed tissue as well as high oral bioavailability, which has been studied in the setting of HAS and been reported to be effective in reducing pain and decreasing anaesthetic consumption in FAI patients (Holmes et al 2013;Kahlenberg et al 2017). One randomized, doubleblinded controlled study in FAI patients who underwent HAS reveals that celecoxib-treated patients have decreased pain (during the acute postoperative period after HAS) and reduced discharge time compared to the placebo-treated patients (Kahlenberg et al 2017).…”

“…Celecoxib, a type of non-steroidal antiinflammatory drug (NSAID), presents with the distinct characteristics including rapid absorption, preferential distribution into inflamed tissue as well as high oral bioavailability, which has been studied in the setting of HAS and been reported to be effective in reducing pain and decreasing anaesthetic consumption in FAI patients (Holmes et al 2013;Kahlenberg et al 2017). One randomized, doubleblinded controlled study in FAI patients who underwent HAS reveals that celecoxib-treated patients have decreased pain (during the acute postoperative period after HAS) and reduced discharge time compared to the placebo-treated patients (Kahlenberg et al 2017). Similarly, another randomized placebo-controlled study in FAI patients who underwent HAS also discloses that celecoxib-treated patients present with improved pain control and accelerated recovery compared to the placebo-treated patients (Zhang et al 2014).…”

“…Celecoxib, a diaryl-substituted pyrazole chemically designated as 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide, is responsible for prostaglandin synthesis inhibition (that is, an integral part of the pain and inflammation pathway) due to selective inhibition of cyclooxygenase-2 (COX-2), which presents with analgesic effect, anti-inflammatory effect as well as antipyretic activity effect (Cohen and Preuss 2019). A few studies have shown that celecoxib has benefits on reducing pain and preventing heterotopic ossification formation in FAI patients who underwent HAS (Cogan et al 2016;Kahlenberg et al 2017). However, whether there are differences between preemptive analgesia and postoperative analgesia of celecoxib in treating FAI patients who underwent HAS is still unclear.…”